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The concept of biobanks can well be explained through
the example of SAPALDIA cohort study which involves
multicentric collection and central storage of blood,
plasma, serum, buffy coat and DNA extracts. Personalized
medicine through genomic sequencing and genetic risk
profiling is very much a possibility with the publication of
genome-wide associations. Even though access to com-
plete genome sequencing is technically feasible the clinical
utility and relevance of DNA sequencing is still very poorly
understood and it should not be assumed that research
will provide answers quickly. Genomics helps in the study
of gene-environment interactions thus contribution to
insights in genetic epidemiology. But genetic testing can
also be a motivating factor for behavioural change.
Limitations in environmental epidemiology of chronic
diseases has left several gaps in understanding the causality
of risk factors, etiological pathways and shared pathways.
The environment and lifestyle varies over time, exposures
are difficult to measure and susceptibilities have been
ignored in the past. Biobanking and genomic studies are
important in understanding the pathways by which risk
factors and behaviours result in chronic diseases in a parti-
cular environmental context.
The exposome concept refers to the exposures of an
individual over a lifetime and the relation of these expo-
sures to health. The exposome changes throughout life as
our bodies, diets and lifestyles change. Measurement of
exposures and their effects are important in describing the
exposome and understanding the interaction between
environmental exposures and genetic and epigenetic
mechanisms. The use of biomarkers to determine expo-
sures, effect of exposures, disease progression and suscept-
ibility factors are common to the “omics” technologies of
genomics, transcriptomics, proteomics and metabonomics.
A blood or urine sample taken from an individual could
provide a snapshot of what that person has been exposed
to. The metabolic profile thus potentially reflects the inter-
actions between the exposome and genome with the abil-
ity to provide insights into causal pathways of complex,
chronic diseases.
Metabonomics refers to the study of metabolic
responses to environmental changes, drugs, genetic
modifications and it involves measurement of small
molecular weight compounds which may act as regula-
tory signals in the biological system. Examples of meta-
bonomic studies include the INTERMAP study which is
a multi-centric investigation into the role of dietary fac-
tors in development of hypertension in adults. Study
populations differ by ethnicity, diet, diet-related major
cardiovascular risk factors and prevalence of hyperten-
sion/coronary heart disease/stroke. Another study invol-
ving identification of urinary metabolites suggests well
differentiated metabolic phenotypes. Most discrimina-
tory metabolites are of dietary origin or gut microbial
co-metabolites. Candidate biomarkers emerging from
other studies include formate for blood pressure, pro-
line-betaine as a marker for citrus consumption and
C-Reactive protein as a marker in the pathway of coron-
ary heart disease. In addition several genetically deter-
mined metabolic phenotypes are also being identified.
The expected benefits from studying exposomes and bio-
markers include decreased exposure misclassification,
identification of early disease markers , assigning causal-
ity, identification of determinants of susceptibility and
the understanding of biological mechanisms . Complex
chronic diseases can be studied through biomarkers of
susceptibility, exposure and disease. Understanding the
differential burden of chronic diseases and risk factors
across different ethnic, cultural and geographic settings
through biomarkers can improve the causal understand-
ing. Establishing mega cohorts and international cohorts
can help better understanding of lifestyle, environment,Correspondence: Nicole.Probst@unibas.ch
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biomarkers and diseases through proper networking.
They provide important policy inputs, maintain and
strengthen competitive research, help scientific and tech-
nological advancement in addition to funding and job
opportunities.
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